TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05814874

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: selenium supplement
Description: Selenium supplement containing 55 µg of sodium selenate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Brazil nut
Description: Brazil nut butter; consumption corresponds to a selenium intake of 55 µg/d

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Brazil nut
Description: Brazil nut butter; consumption corresponds to a selenium intake of 55 µg/d

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill
Study: NCT06105463

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength training sessions and High-interval intensity training sessions
Description: During strength training sessions, participants will perform 4 lower limb exercises, including bilateral leg press, unilateral leg extension, unilateral hip extension, and bilateral seated calf raise on conventional weight machines. The intensity of the session will be 70-75% of 1-RM, 4 sets, 10 repetitions (1-2 RIR) and 120 seconds rest between sets.~During High-interval intensity training (HIIT) sessions, participants will perform 10 minutes of warm-up at 50% of peak power + 20 minutes of HIIT consisting of 30 seconds at 90% of peak power followed by 30 seconds of rest + 10 minutes of cool-down at 35-40% of peak power in cycloergometer.
Study: NCT04950907

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: vats
Description: Use uniportal tubeless VATS to obtain the biopsy
Study: NCT05039775

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EROS device
Description: Eros is a small, hand-held device fitted with a removable, replaceable small plastic cup used as a natural way to initiate female sexual response. It was originally cleared by the FDA in April 2000 for the treatment of Female Sexual Arousal Disorder (FSAD), which includes problems with sexual arousal and orgasm.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychosexual support
Description: Strategies are suggested to improve the couple's emotional connection and communication, when couples are being consulted, they are encouraged to focus on the strengths as well as weaknesses in their relationship. Homework assignments are given for the couple to practice skills, such as turning the idea of sexual obligation into pleasure, learning to focus on sensations rather than anxieties and communicating openly with their partner.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosexual support
Description: Strategies are suggested to improve the couple's emotional connection and communication, when couples are being consulted, they are encouraged to focus on the strengths as well as weaknesses in their relationship. Homework assignments are given for the couple to practice skills, such as turning the idea of sexual obligation into pleasure, learning to focus on sensations rather than anxieties and communicating openly with their partner.
Study: NCT04268836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optimal Acuity Clear-K® Low Vision Aid System treatment
Description: The treatment involves irradiation of the cornea with low energy light in a treatment pattern that produces corneal shape change.
Study: NCT04950907

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CT-guided fine needle biopsy
Description: Use CT-guided fine needle to obtain the biopsy
Study: NCT04805372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VD+VF group
Description: where they should review a video of an expert performing central vein operation and a video of their own most recent operation, before returning to do another operation. This will be repeated for a total of 5 central vein cannulation encounters and 5 video reviews.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: VD group
Description: where they should review a video of an expert performing central vein operation before returning to do another operation. This will be repeated for a total of 5 central vein cannulation encounters and 5 video reviews.
Study: NCT06497660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxyadrenaline
Description: Deoxyadrenaline is a vasoactive drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxyadrenaline
Description: Deoxyadrenaline is a vasoactive drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxyadrenaline
Description: Deoxyadrenaline is a vasoactive drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Deoxyadrenaline
Description: Deoxyadrenaline is a vasoactive drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline
Description: Deoxyadrenaline is a vasoactive drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline
Description: Deoxyadrenaline is a vasoactive drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline
Description: Deoxyadrenaline is a vasoactive drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Deoxyadrenaline is a vasoactive drug
Study: NCT06320275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Storytelling Intervention
Description: A storytelling fertility awareness video intervention, approximately 10 minutes in length, guided by a situation-specific theoretical framework and storytelling/narrative communication theory, was developed by the researchers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Storytelling Intervention
Description: A storytelling fertility awareness video intervention, approximately 10 minutes in length, guided by a situation-specific theoretical framework and storytelling/narrative communication theory, was developed by the researchers.
Study: NCT05451511

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Door-In-The-Face Technique
Description: Sequential request strategies will be applied as an intervention. For the Door-In-The-Face Technique, participants first receive a large request they are unlikely to accept, followed by a smaller request that is the true behavior of interest.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Foot-In-The-Door Technique
Description: Sequential request strategies will be applied as an intervention. For the Foot-In-The-Door Technique, participants are shown an easier first request that they are likely to accept, followed by a larger request that is not the behavior of interest.
Study: NCT05424861

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acupressure group
Description: A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points open. The most preferred points LI4 and SP6 were selected among the points that were reported to be effective in relieving luterus pain by scanning the literature on the points to be compressed. Acupressure will be applied to the points (bidirectional, right and left) for 2 minutes, for a total of 8 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it is passed to the other point in the symmetrical region and the application is made without interruption. While practicing, the researcher will check the time using a digital wristwatch with a stopwatch.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: No application will be made. The mothers in this group will fill in the visual analog scale, which evaluates postpartum uterine pain 3 times between 6-24 hours after birth.
Study: NCT04581447

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Standardized meal
Description: Measurements of metformin-induced enterohormones secretion will be done after standardized meal test in a subgroup of patients (ancillary study)
Study: NCT05500066

Intervention type: DEVICE
Intervention: Aequalis Flex Revive Shoulder System
Description: The AEQUALIS FLEX REVIVE Shoulder System is intended for use as:~* A replacement of shoulder joints in primary anatomic or in primary reverse~* A replacement of other shoulder joints devices in case of revisions if sufficient bone stock remains.~The system also allows for conversion from anatomic to reverse shoulder prosthesis in case of revision.
Study: NCT05578157

Intervention type: DIAGNOSTIC_TEST
Intervention: Feeling Hot sensor
Description: The Feeling Hot sensor is a proof-of-concept system, which can measure overnight penile, thigh and air temperature.

Intervention type: DIAGNOSTIC_TEST
Intervention: Feeling Hot sensor
Description: The Feeling Hot sensor is a proof-of-concept system, which can measure overnight penile, thigh and air temperature.

Intervention type: DIAGNOSTIC_TEST
Intervention: Feeling Hot sensor
Description: The Feeling Hot sensor is a proof-of-concept system, which can measure overnight penile, thigh and air temperature.
Study: NCT05742347

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DriGo Skin Protectant Textile
Description: All participants in this study will have the DriGo skin protectant textile applied to their skin fold condition. Erythema, denudation, maceration, odor, and moisture will be assessed following application of the SPT.
Study: NCT06164210

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Snoezelen-Based Occupational Therapy Intervention Group
Description: Snoezelen- Based Occupational Therapy Intervention Different from sensory integration interventions, Snoezelen-based interventions are environments with all sensory stimuli, such as auditory, visual, tactile, gustatory, olfactory, and vestibular stimuli, in the same environment and where therapeutic guidance and commands are not given to the individual. These interventions aim to reduce agitation, depression, and aggression in individuals and increase daily living activities, functional performance, and well-being. Psychiatric clinics, schools, rehabilitation centers, and occupational therapy clinics are some places where it is used. Some materials found in Snoezelen rooms are bubble tubes, fiber optic light cables, projectors, vibrating massagers, light tactile stimulation materials, aromatic scent emitting devices, music sets, and relaxing music and swings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Snoezelen-Based Occupational Therapy Intervention Group
Description: Snoezelen- Based Occupational Therapy Intervention Different from sensory integration interventions, Snoezelen-based interventions are environments with all sensory stimuli, such as auditory, visual, tactile, gustatory, olfactory, and vestibular stimuli, in the same environment and where therapeutic guidance and commands are not given to the individual. These interventions aim to reduce agitation, depression, and aggression in individuals and increase daily living activities, functional performance, and well-being. Psychiatric clinics, schools, rehabilitation centers, and occupational therapy clinics are some places where it is used. Some materials found in Snoezelen rooms are bubble tubes, fiber optic light cables, projectors, vibrating massagers, light tactile stimulation materials, aromatic scent emitting devices, music sets, and relaxing music and swings.
Study: NCT05198778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: URC102
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: URC102
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: URC102
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: URC102
Description: tablet
Study: NCT04776044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-002
Description: 150mg tablets for oral intake

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching tablets for oral intake
Study: NCT05188365

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: true acupuncture
Description: different body acupuncture points will be selected to be manually punctured in addition to 4 acupoints on the skin of abdominal surface (the four points will be electrical stimulated during acupuncture). the session (20 minutes) will repeated thrice weekly. the total duration of the study will be 60 days.~The points that will be manually acupunctured all over the body of every patient will be: SJ(3)/SJ(5)/SJ(17)/SJ(18)/SJ(19)/SJ(20)/SJ(21)/SJ(22)/GB(2)/GB(8)/GB(20)/LI(4)/LI(11)/KI(3)/SP(6)/ST(36)/REN(4)/REN(9)/REN(12)~The acupuncture points that will be electrically stimulated on the abdomen of every patient will be: bilateral Stomach 25 in addition to gallbladder 28 acupoints.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: different body acupuncture points will be selected to be manually punctured in addition to 4 acupoints on the skin of abdominal surface (the four points will be electrical stimulated during acupuncture). opposite to group A, in this group, the acupuncture needles will be inserted manually and very adjacent to the real location of group-A acupoints (sham acupuncture). The electrical stimulator will connected to abdominal acupoints (bilateral Stomach 25 in addition to gallbladder 28 acupoints) but it will be turned off during the sessions. the session will repeated thrice weekly. the total duration of the study will be 60 days
Study: NCT06628297

Intervention type: DIAGNOSTIC_TEST
Intervention: PET
Description: PET imaging will be performed with a Discovery 710 PET/CT scanner (GE Healthcare, Milwaukee, WI, USA). Four 5-minute PET recordings will be performed of each subject within a single scanning session of 70 min. Two consecutive 5-minute scans are conducted of the heart and brain in rest. \[15O\]H2O, is produced on-site (GENtrace, GE, Uppsala, Sweden), and 600 MBq \[15O\]H2O is intravenously injected by an automatic Hidex Radiowater Generator (Hidex, Turku, Finland). To induce heart vasodilation, adenosine is infused (140 g/kg/min) for 6 min and a scan of the heart is repeated. To induce brain vasodilation, 1 g of acetazolamide is infused over 5 min and 15 min later the brain is scanned. Myocardial perfusion is calculated using CarimasCE software version 1.3.1. (Turku, Finland). Cerebral perfusion is calculated using PMOD software (PMOD Technologies, Switzerland).

Intervention type: DIAGNOSTIC_TEST
Intervention: PET
Description: PET imaging will be performed with a Discovery 710 PET/CT scanner (GE Healthcare, Milwaukee, WI, USA). Four 5-minute PET recordings will be performed of each subject within a single scanning session of 70 min. Two consecutive 5-minute scans are conducted of the heart and brain in rest. \[15O\]H2O, is produced on-site (GENtrace, GE, Uppsala, Sweden), and 600 MBq \[15O\]H2O is intravenously injected by an automatic Hidex Radiowater Generator (Hidex, Turku, Finland). To induce heart vasodilation, adenosine is infused (140 g/kg/min) for 6 min and a scan of the heart is repeated. To induce brain vasodilation, 1 g of acetazolamide is infused over 5 min and 15 min later the brain is scanned. Myocardial perfusion is calculated using CarimasCE software version 1.3.1. (Turku, Finland). Cerebral perfusion is calculated using PMOD software (PMOD Technologies, Switzerland).
Study: NCT05658393

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ReLiver-N App
Description: Web-based mobile health application for patients with liver cirrhosis

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ReLiver-N App
Description: Web-based mobile health application for patients with liver cirrhosis
Study: NCT05641623

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OSU6162
Description: OSU6162

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05269511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine is in the form of granules (9 g/sachet), which is comprised of ten medicinal herbs.
Description: Oral administration, twice per day.
Study: NCT05541471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Syrup for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Tablets for oral administration.
Study: NCT05992909

Intervention type: PROCEDURE
Intervention: Lymphovenous bypass procedure
Description: Participants will return to the clinic 14 days, 6 months, 12 months, 18 months, and 24 months after your surgery for measurements of your legs to see if there are changes over time
Study: NCT05443048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ivoclar Ivotion Denture System
Description: Fabrication of maxillary and mandibular complete removable dental prosthesis with the Ivoclar Ivotion Denture System
Study: NCT04794621

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroceutical Dressing Technology-EDThi
Description: Use of EDThi for 3 weeks post enrollment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adding EDTlo (Procellera®) for 3 weeks after use of EDThi
Description: Use of EDTlo (Procellera®) for additional 3 weeks
Study: NCT05861401

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Janus Kinase 1 and 2
Description: Under complete sterile precautions, 3mL of blood will be withdrawn by venipuncture and put in EDTA tube; DNA extraction will be done after centrifugation and used for genotyping assay of (JAK 1 and JAK2) gene with the polymerase chain reaction(PCR).

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Janus Kinase 1 and 2
Description: Under complete sterile precautions, 3mL of blood will be withdrawn by venipuncture and put in EDTA tube; DNA extraction will be done after centrifugation and used for genotyping assay of (JAK 1 and JAK2) gene with the polymerase chain reaction(PCR).
Study: NCT04754061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Phase 1 (week 1): all enrolled participants will take a single 1mg oral dose of psilocybin once per day on Monday and Thursday. If no adverse events are reported at any point during the week (Mon-Fri), the participant will continue to Phase 2 for week 2.~Phase 2: The participant will take a single 1mg oral dose of psilocybin once per day for 5 consecutive days (Monday to Friday). If no adverse events are reported at any point during the week (Mon-Fri), the participant will continue to Phase 3 for week 3.~Phase 3: The participant will take two 1mg oral doses (2mg total) of psilocybin once per day for 5 consecutive days (Monday to Friday). If no adverse events are reported at any point during the week (Mon-Fri), the participant will continue to Phase 4 for week 4.~Phase 4 (maximum allowable dose): The participant will take three 1mg oral doses (3mg total) of psilocybin once per day for 5 consecutive days (Monday to Friday).
Study: NCT06253208

Intervention type: PROCEDURE
Intervention: postoperative pain
Description: Postoperative analgesia in laparoscopic sleeve gastrectomies: laparoscopic versus ultrasound-guided transversus abdominis plane block

Intervention type: PROCEDURE
Intervention: postoperative pain
Description: Postoperative analgesia in laparoscopic sleeve gastrectomies: laparoscopic versus ultrasound-guided transversus abdominis plane block
Study: NCT05995340

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELAPR002f Injectable Gel
Description: Intradermal Injections

Intervention type: OTHER
Group type: OTHER
Intervention: Saline Active Control
Description: Intradermal Injections
Study: NCT04707391

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MenABCWY vaccine
Description: 2 doses of MenABCWY vaccine administered intramuscularly on Day 1 and Day 181 to participants in ABCWY group.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 dose of placebo administered intramuscularly on Day 211 to participants in ABCWY group

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY vaccine
Description: 1 dose of MenACWY vaccine administered intramuscularly on Day 1 to participants in ACWY group

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: MenB vaccine
Description: 2 doses of MenB vaccine administered intramuscularly on Day 181 and Day 211 to participants in ACWY group. MenB vaccine is a non-investigational medical product (NIMP) in this study and is administered only in compliance with standard of care.
Study: NCT03278730

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Para-Tyrosine supplementation
Description: Patients will recieve the study drug during their stay at the ICU, but for a maximum of 7 days. The study drug is 3x2 gramms of para-Tyrosine, which will be dispensed and administered in a form of oral suspension via a nasogastric tube.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: Patients will recieveplacebo during their stay at the ICU, but for a maximum of 7 days. The study drug is 3x2 gramms of placebo, which will be dispensed and administered in a form of oral suspension via a nasogastric tube.
Study: NCT05131321

Intervention type: PROCEDURE
Intervention: Primary ankle arthrodesis (fusion)
Description: Primary arthrodesis: Subjects allocated to the fusion group will have insertion of a retrograde locked calcaneal nail. Tibiotalar joint preparation, bone grafting, subtalar preparation, and fibulectomy will not be performed unless deemed necessary by the treating surgeon.

Intervention type: PROCEDURE
Intervention: ORIF (open reduction and internal fixation)
Description: ORIF: ORIF will be performed using modern techniques for timing and staging of fixation, soft tissue and fibula management, surgical approaches, reduction techniques, and plate choice.

Intervention type: PROCEDURE
Intervention: Intramedullary Fibular Nailing (IMFN)
Description: Intramedullary Fibular Nailing: Participants allocated to the IMFN group will receive a locked fibular nail using a previously described technique.